Teva : TEVA

All Teva Articles

450 Articles

Jon C. Ogg | Mar 14, 2014 at 8:20 AM EDT

Top Analyst Upgrades and Downgrades: Alcoa, NetApp, Plug Power, Teva and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 14, 2014.…

Trey Thoelcke | Mar 13, 2014 at 8:45 AM EDT

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically…

Jon C. Ogg | Mar 7, 2014 at 8:35 AM EST

Top Analyst Upgrades and Downgrades: Nokia, Safeway, Sirius XM, Skull Candy, Teva, and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 7, 2014.…

Trey Thoelcke | Feb 26, 2014 at 8:25 AM EST

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added…

Jon C. Ogg | Feb 6, 2014 at 7:30 AM EST

Teva Delivers on Earnings in Turnaround

Teva Pharmaceutical Industries is out with its fourth-quarter earnings report, and it looks as though the bad trends may be…

Jon C. Ogg | Jan 27, 2014 at 11:05 AM EST

Analyst Team Sees Strong Biotech Buyout Market in 2014

Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report…

Trey Thoelcke | Jan 22, 2014 at 7:30 AM EST

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade.…

Jon C. Ogg | Jan 7, 2014 at 8:15 AM EST

Top Analyst Upgrades and Downgrades: Capital One, Chesapeake, LinkedIn, Lululemon, Netflix and More

These arethe top analyst upgrades, downgrades and initiations seen from Wall Street research firms for Tuesday, January 7.

Jon C. Ogg | Dec 30, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.

Trey Thoelcke | Dec 27, 2013 at 7:01 AM EST

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

ThinkstockWith less than a week left in what has been the best year for the S&P 500 since 1997, we…

Trey Thoelcke | Dec 18, 2013 at 7:00 AM EST

Teva Secures Rights to Launch Generic Viagra

ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020,…

Jon C. Ogg | Dec 10, 2013 at 10:10 AM EST

Teva Prospects Keep Dimming, Even If 2014 Sales Drop-Off Limited

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) has moved from a great growth story to one of promise, to one of…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

Jon C. Ogg | Nov 4, 2013 at 8:25 AM EST

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, BP, Gap, Teva and More

Jon OggThis week marks the beginning of the end for earnings season, and both the Dow Jones Industrial Average and S&P…

Trey Thoelcke | Oct 30, 2013 at 7:10 AM EDT

Teva Pharmaceutical Shares Plunge on CEO Resignation

ThinkstockAfter denying rumors earlier this week that its CEO was considering resigning, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced Wednesday…

1 … 21 22 23 24 25 … 30

Teva : TEVA

All Teva Articles

Top Analyst Upgrades and Downgrades: Alcoa, NetApp, Plug Power, Teva and More

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

Top Analyst Upgrades and Downgrades: Nokia, Safeway, Sirius XM, Skull Candy, Teva, and More

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Teva Delivers on Earnings in Turnaround

Analyst Team Sees Strong Biotech Buyout Market in 2014

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Top Analyst Upgrades and Downgrades: Capital One, Chesapeake, LinkedIn, Lululemon, Netflix and More

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

Teva Secures Rights to Launch Generic Viagra

Teva Prospects Keep Dimming, Even If 2014 Sales Drop-Off Limited

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, BP, Gap, Teva and More

Teva Pharmaceutical Shares Plunge on CEO Resignation

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Teva : TEVA

All Teva Articles

Top Analyst Upgrades and Downgrades: Alcoa, NetApp, Plug Power, Teva and More

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

Top Analyst Upgrades and Downgrades: Nokia, Safeway, Sirius XM, Skull Candy, Teva, and More

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Teva Delivers on Earnings in Turnaround

Analyst Team Sees Strong Biotech Buyout Market in 2014

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Top Analyst Upgrades and Downgrades: Capital One, Chesapeake, LinkedIn, Lululemon, Netflix and More

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Ten Top Stocks Trading Under $10 to Buy for Big 2014 Gains

Teva Secures Rights to Launch Generic Viagra

Teva Prospects Keep Dimming, Even If 2014 Sales Drop-Off Limited

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, BP, Gap, Teva and More

Teva Pharmaceutical Shares Plunge on CEO Resignation

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do